Immunotherapy

Papers
(The H4-Index of Immunotherapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study84
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study68
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia47
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’37
Imaging of brain metastases treated with immune checkpoint inhibitors34
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar33
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma30
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study28
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma27
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas26
Postvaccination immune-mediated hepatitis: what do we really know?22
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15821
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?18
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data17
Immunotherapy for Gastric Cancer: A 2021 Update17
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis17
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression17
0.1465950012207